The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole.
Identifieur interne : 009356 ( Main/Exploration ); précédent : 009355; suivant : 009357The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole.
Auteurs : R K Shenoy [Inde] ; T K Suma ; A. John ; S R Arun ; V. Kumaraswami ; L L Fleckenstein ; K. Na-BangchangSource :
- Annals of tropical medicine and parasitology [ 0003-4983 ] ; 2002.
Descripteurs français
- KwdFr :
- Administration par voie orale, Adolescent, Adulte, Adulte d'âge moyen, Albendazole (effets indésirables), Albendazole (sang), Association de médicaments, Chromatographie en phase gazeuse, Chromatographie en phase liquide à haute performance, Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (sang), Femelle, Filaricides (effets indésirables), Filaricides (sang), Filariose lymphatique (métabolisme), Filariose lymphatique (traitement médicamenteux), Humains, Interactions médicamenteuses, Mâle, Méthode en double aveugle.
- MESH :
- effets indésirables : Albendazole, Diéthylcarbamazine, Filaricides.
- métabolisme : Filariose lymphatique.
- sang : Albendazole, Diéthylcarbamazine, Filaricides.
- traitement médicamenteux : Filariose lymphatique.
- Administration par voie orale, Adolescent, Adulte, Adulte d'âge moyen, Association de médicaments, Chromatographie en phase gazeuse, Chromatographie en phase liquide à haute performance, Femelle, Humains, Interactions médicamenteuses, Mâle, Méthode en double aveugle.
English descriptors
- KwdEn :
- Administration, Oral, Adolescent, Adult, Albendazole (adverse effects), Albendazole (blood), Chromatography, Gas, Chromatography, High Pressure Liquid, Diethylcarbamazine (adverse effects), Diethylcarbamazine (blood), Double-Blind Method, Drug Interactions, Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (metabolism), Female, Filaricides (adverse effects), Filaricides (blood), Humans, Male, Middle Aged.
- MESH :
- chemical , adverse effects : Albendazole, Diethylcarbamazine, Filaricides.
- chemical , blood : Albendazole, Diethylcarbamazine, Filaricides.
- drug therapy : Elephantiasis, Filarial.
- metabolism : Elephantiasis, Filarial.
- Administration, Oral, Adolescent, Adult, Chromatography, Gas, Chromatography, High Pressure Liquid, Double-Blind Method, Drug Interactions, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Abstract
The pharmacokinetics, safety and tolerability of single, oral doses of diethylcarbamazine (DEC) and albendazole, given alone or in combination, were investigated in a double-blind, randomized and placebo-controlled trial involving 42 amicrofilaraemic subjects living in an area of India where lymphatic filariasis is endemic. The subjects (34 males and eight females, aged 18-52 years and weighing 46-66.5 kg) were randomly allocated to one of the three drug groups. Fourteen were given just DEC (6 mg/kg), another 14 were given just albendazole (400 mg) and the remaining 14 were given both DEC (6 mg/kg) and albendazole (400 mg). Blood samples for pharmacokinetic study were collected at specified intervals before and after drug administration. Plasma concentrations of DEC and albendazole/albendazole sulphoxide were estimated using gas chromatography and HPLC, respectively. The safety and tolerability of the treatments were evaluated through clinical and laboratory assessments. Both the DEC and albendazole were well tolerated when given alone or in combination, no adverse events being observed. In all three treatment groups, the drugs were rapidly absorbed from the gastro-intestinal tract although there was marked inter-individual#10; variation. The pharmacokinetics of DEC, albendazole and albendazole sulphoxide were similar, whether each drug was given alone or in combination. These results indicate that there is no adverse pharmacokinetic or pharmacodynamic reason why DEC and albendazole should not be co-administered to control lymphatic filariasis.
DOI: 10.1179/000349802125001663
PubMed: 12396323
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004446
- to stream PubMed, to step Curation: 004446
- to stream PubMed, to step Checkpoint: 004446
- to stream Ncbi, to step Merge: 000B43
- to stream Ncbi, to step Curation: 000B43
- to stream Ncbi, to step Checkpoint: 000B43
- to stream Main, to step Merge: 009679
- to stream Main, to step Curation: 009356
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole.</title><author><name sortKey="Shenoy, R K" sort="Shenoy, R K" uniqKey="Shenoy R" first="R K" last="Shenoy">R K Shenoy</name><affiliation wicri:level="1"><nlm:affiliation>Filariasis Chemotherapy Unit, T.D. Medical College Hospital, Alappuzha - 688 011, India. rkshenoy2000@yahoo.com</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Filariasis Chemotherapy Unit, T.D. Medical College Hospital, Alappuzha - 688 011</wicri:regionArea><wicri:noRegion>Alappuzha - 688 011</wicri:noRegion></affiliation></author><author><name sortKey="Suma, T K" sort="Suma, T K" uniqKey="Suma T" first="T K" last="Suma">T K Suma</name></author><author><name sortKey="John, A" sort="John, A" uniqKey="John A" first="A" last="John">A. John</name></author><author><name sortKey="Arun, S R" sort="Arun, S R" uniqKey="Arun S" first="S R" last="Arun">S R Arun</name></author><author><name sortKey="Kumaraswami, V" sort="Kumaraswami, V" uniqKey="Kumaraswami V" first="V" last="Kumaraswami">V. Kumaraswami</name></author><author><name sortKey="Fleckenstein, L L" sort="Fleckenstein, L L" uniqKey="Fleckenstein L" first="L L" last="Fleckenstein">L L Fleckenstein</name></author><author><name sortKey="Na Bangchang, K" sort="Na Bangchang, K" uniqKey="Na Bangchang K" first="K" last="Na-Bangchang">K. Na-Bangchang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12396323</idno><idno type="pmid">12396323</idno><idno type="doi">10.1179/000349802125001663</idno><idno type="wicri:Area/PubMed/Corpus">004446</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004446</idno><idno type="wicri:Area/PubMed/Curation">004446</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004446</idno><idno type="wicri:Area/PubMed/Checkpoint">004446</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004446</idno><idno type="wicri:Area/Ncbi/Merge">000B43</idno><idno type="wicri:Area/Ncbi/Curation">000B43</idno><idno type="wicri:Area/Ncbi/Checkpoint">000B43</idno><idno type="wicri:doubleKey">0003-4983:2002:Shenoy R:the:pharmacokinetics:safety</idno><idno type="wicri:Area/Main/Merge">009679</idno><idno type="wicri:Area/Main/Curation">009356</idno><idno type="wicri:Area/Main/Exploration">009356</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole.</title><author><name sortKey="Shenoy, R K" sort="Shenoy, R K" uniqKey="Shenoy R" first="R K" last="Shenoy">R K Shenoy</name><affiliation wicri:level="1"><nlm:affiliation>Filariasis Chemotherapy Unit, T.D. Medical College Hospital, Alappuzha - 688 011, India. rkshenoy2000@yahoo.com</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Filariasis Chemotherapy Unit, T.D. Medical College Hospital, Alappuzha - 688 011</wicri:regionArea><wicri:noRegion>Alappuzha - 688 011</wicri:noRegion></affiliation></author><author><name sortKey="Suma, T K" sort="Suma, T K" uniqKey="Suma T" first="T K" last="Suma">T K Suma</name></author><author><name sortKey="John, A" sort="John, A" uniqKey="John A" first="A" last="John">A. John</name></author><author><name sortKey="Arun, S R" sort="Arun, S R" uniqKey="Arun S" first="S R" last="Arun">S R Arun</name></author><author><name sortKey="Kumaraswami, V" sort="Kumaraswami, V" uniqKey="Kumaraswami V" first="V" last="Kumaraswami">V. Kumaraswami</name></author><author><name sortKey="Fleckenstein, L L" sort="Fleckenstein, L L" uniqKey="Fleckenstein L" first="L L" last="Fleckenstein">L L Fleckenstein</name></author><author><name sortKey="Na Bangchang, K" sort="Na Bangchang, K" uniqKey="Na Bangchang K" first="K" last="Na-Bangchang">K. Na-Bangchang</name></author></analytic><series><title level="j">Annals of tropical medicine and parasitology</title><idno type="ISSN">0003-4983</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Adolescent</term><term>Adult</term><term>Albendazole (adverse effects)</term><term>Albendazole (blood)</term><term>Chromatography, Gas</term><term>Chromatography, High Pressure Liquid</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (blood)</term><term>Double-Blind Method</term><term>Drug Interactions</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (metabolism)</term><term>Female</term><term>Filaricides (adverse effects)</term><term>Filaricides (blood)</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Albendazole (effets indésirables)</term><term>Albendazole (sang)</term><term>Association de médicaments</term><term>Chromatographie en phase gazeuse</term><term>Chromatographie en phase liquide à haute performance</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Diéthylcarbamazine (sang)</term><term>Femelle</term><term>Filaricides (effets indésirables)</term><term>Filaricides (sang)</term><term>Filariose lymphatique (métabolisme)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Mâle</term><term>Méthode en double aveugle</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adolescent</term><term>Adult</term><term>Chromatography, Gas</term><term>Chromatography, High Pressure Liquid</term><term>Double-Blind Method</term><term>Drug Interactions</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Chromatographie en phase gazeuse</term><term>Chromatographie en phase liquide à haute performance</term><term>Femelle</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Mâle</term><term>Méthode en double aveugle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The pharmacokinetics, safety and tolerability of single, oral doses of diethylcarbamazine (DEC) and albendazole, given alone or in combination, were investigated in a double-blind, randomized and placebo-controlled trial involving 42 amicrofilaraemic subjects living in an area of India where lymphatic filariasis is endemic. The subjects (34 males and eight females, aged 18-52 years and weighing 46-66.5 kg) were randomly allocated to one of the three drug groups. Fourteen were given just DEC (6 mg/kg), another 14 were given just albendazole (400 mg) and the remaining 14 were given both DEC (6 mg/kg) and albendazole (400 mg). Blood samples for pharmacokinetic study were collected at specified intervals before and after drug administration. Plasma concentrations of DEC and albendazole/albendazole sulphoxide were estimated using gas chromatography and HPLC, respectively. The safety and tolerability of the treatments were evaluated through clinical and laboratory assessments. Both the DEC and albendazole were well tolerated when given alone or in combination, no adverse events being observed. In all three treatment groups, the drugs were rapidly absorbed from the gastro-intestinal tract although there was marked inter-individual#10; variation. The pharmacokinetics of DEC, albendazole and albendazole sulphoxide were similar, whether each drug was given alone or in combination. These results indicate that there is no adverse pharmacokinetic or pharmacodynamic reason why DEC and albendazole should not be co-administered to control lymphatic filariasis.</div></front></TEI><affiliations><list><country><li>Inde</li></country></list><tree><noCountry><name sortKey="Arun, S R" sort="Arun, S R" uniqKey="Arun S" first="S R" last="Arun">S R Arun</name><name sortKey="Fleckenstein, L L" sort="Fleckenstein, L L" uniqKey="Fleckenstein L" first="L L" last="Fleckenstein">L L Fleckenstein</name><name sortKey="John, A" sort="John, A" uniqKey="John A" first="A" last="John">A. John</name><name sortKey="Kumaraswami, V" sort="Kumaraswami, V" uniqKey="Kumaraswami V" first="V" last="Kumaraswami">V. Kumaraswami</name><name sortKey="Na Bangchang, K" sort="Na Bangchang, K" uniqKey="Na Bangchang K" first="K" last="Na-Bangchang">K. Na-Bangchang</name><name sortKey="Suma, T K" sort="Suma, T K" uniqKey="Suma T" first="T K" last="Suma">T K Suma</name></noCountry><country name="Inde"><noRegion><name sortKey="Shenoy, R K" sort="Shenoy, R K" uniqKey="Shenoy R" first="R K" last="Shenoy">R K Shenoy</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009356 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009356 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12396323
|texte= The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12396323" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |